Quick Answer
ADC Therapeutics SA reported Stockholders Equity of -$185.83 million for fiscal year 2025.
ADC Therapeutics SA Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$185.83M | +8.3% |
| 2024 | -$202.64M | -36.7% |
| 2023 | -$148.25M | -286.6% |
| 2022 | $79.45M | -48.4% |
| 2021 | $154.03M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$238.18M | -38.5% | -19.6% |
| June 30, 2025 | -$199.18M | -51.3% | +16.4% |
| March 31, 2025 | -$238.22M | -22.5% | -17.6% |
| December 31, 2024 | -$202.64M | -36.7% | -17.9% |
| September 30, 2024 | -$171.95M | -167.6% | -30.6% |
| June 30, 2024 | -$131.67M | -568.5% | +32.3% |
| March 31, 2024 | -$194.45M | -784.1% | -31.2% |
| December 31, 2023 | -$148.25M | -286.6% | -130.8% |
- ADC Therapeutics SA showed an increase of +8.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, ADC Therapeutics SA’s stockholders equity has declined by 220.7% (from $154.03 million to -$185.83 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: